Kezar Life Sciences, Inc.
kezarlifesciences.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 11, 2026. Its latest SEC filing is a SCHEDULE 13G/A from May 28, 2026.
10-Q for Q1 FY2026, filed May 11, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops small-molecule drug candidates for patients with immune-mediated diseases, including zetomipzomib for autoimmune hepatitis.
10-K for FY2025, filed Mar 27, 2026We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated…View ↗
Our product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor in development for the treatment of severe…View ↗
Zetomipzomib is a clinical development candidate for AIH, a rare, chronic disease in which the immune system attacks the liver and causes…View ↗
Who Were Their Customers?
Everest Medicines II (HK) Limited is a license partner with exclusive rights to develop and commercialize zetomipzomib in the Greater China region and several Asian markets.
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 11, 2026
−$5.8MView ↗
- ▼ −65% (Loss)
- vs −$16.6M in Q1 FY2025
-
May 11, 2026
Aurinia completed its acquisition of Kezar
Kezar became a wholly owned Aurinia subsidiary, and each eligible share converted into cash plus a contingent value right.
Sources
8-K, filed May 11, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on May 11, 2026, Parent completed a tender…View ↗
-
Apr 3, 2026
CEO and CFO agreed to leave at merger closing
Sources
8-K, filed Apr 3, 2026
On April 1, 2026, the Company and each of Christopher J. Kirk, Ph.D., the Company’s Chief Executive Officer, Marc L. Belsky, the Company’s…View ↗
-
Mar 30, 2026
Kezar agreed to be acquired by Aurinia
The proposed consideration combined cash per share with a contingent value right tied to development, asset-sale proceeds and excess closing cash.
Sources
8-K, filed Mar 30, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Parent will cause Merger Sub to commence a cash…View ↗
Protein-secretion assets sold
The earlier report described zetomipzomib for immune-mediated diseases alongside a protein-secretion program for cancer and autoimmune conditions. The latest report centers on zetomipzomib and says those program assets were sold to Enodia.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 27, 2026
Loading...
